

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Persky, Daniel O.		POSITION TITLE	
eRA COMMONS USER NAME (credential, e.g., agency login) DPersky		Associate Professor of Medicine	
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.)			
INSTITUTION AND LOCATION	DEGREE (if applicable)	MM/YY	FIELD OF STUDY
Harvard University, Cambridge, MA	A.B.	06/96	Biochemistry
Albert Einstein College of Medicine, Bronx, NY	M.D.	06/00	Medicine
Mayo Graduate School of Medicine, Rochester, MN	Residency	06/03	Internal Medicine
Memorial Sloan-Kettering Cancer Center, New York, NY	Fellowship	06/06	Medical Oncology and Hematology

A. Personal Statement

I am a medical oncologist conducting clinical research in lymphoid malignancies. My major research interest is using disease biology to guide therapeutic development. I am a member of the SWOG Lymphoma Committee and serve as a Principal Investigator on two national clinical trials in aggressive lymphoma. I also develop investigator-initiated clinical trials, and serve as the chair of Data and Safety Monitoring Board for the University of Arizona Cancer Center.

B. Positions and Honors**Positions and Employment**

07/2006 – 06/2012 Assistant Professor of Medicine, University of Arizona Cancer Center, Department of Internal Medicine, Section of Hematology/Oncology
08/2012 – 10/2013 Assistant Professor of Medicine (Hematology), Yale Cancer Center
11/2013 – present Associate Professor of Medicine, University of Arizona Cancer Center, Department of Internal Medicine, Section of Hematology/Oncology

Other Experience and Professional Memberships

2004 - present Member, American Society of Hematology
2004 - present Member, American Society of Clinical Oncology
2007 - present Lymphoma Committee member, SWOG (Southwest Oncology Group)

Honors and Awards

1992-1996 Harvard College Scholarship
1994, 1995 Ford Research Grant
1997 National Cancer Institute Research Fellowship
2002 Poster Finalist, ACP Minnesota and National Associates Research Competition
2004, 2005 Mortimer J. Lacher Fellowship Award
2005 ASH Clinical Research Training Institute
2005 ASH Travel Award
2007 SWOG Young Investigator Training Award
2010 SWOG Coltman Fellowship Award
2012 NIH Loan Repayment Program

C. Selected Peer-Reviewed Publications

1. Porrata LF, Litzow MR, Inwards DJ, Gastineau DA, Moore SB, Pineda AA, Bundy KL, Padley DJ, **Persky D**, Ansell SM, Micallef IN, Markovic SN. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma. *Bone Marrow Transplant*. 2004 Feb;33(3):291-8. PMID: 14676784.
2. **Persky DO**, Unger JM, Spier CM, Stea B, LeBlanc M, McCarty MJ, Rimsza LM, Fisher RI, and Miller TP. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group Study 0014. *J Clin Oncol* 2008 May 10;26(14):2258-63. Epub 2008 Apr 14. PMID: 18413640.
3. Rimsza LM, Leblanc ML, Unger JM, Miller TP, Grogan TM, **Persky DO**, Martel RR, Sabalos CM, Seligmann B, Brazier RM, Campo E, Rosenwald A, Connors JM, Sehn LH, Johnson N, Gascoyne RD. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. *Blood* 2008 Oct 15;112(8):3425-33. Epub 2008 Jun 10. PMID: 18544678.
4. Stopeck AT, Unger JM, Rimsza LM, Bellamy WT, Iannone M, **Persky DO**, Leblanc M, Fisher RI, Miller TP. A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest Oncology Group Study S0108. *Leuk Lymphoma* 2009 May;50(5):728-35. Epub 2009 Apr 15. PMID: 19373598; PMCID: PMC3532923.
5. **Persky DO**, Moskowitz, CH, Filatov A, Saxena R, Haiyan C, Teruya-Feldstein. J. High dose chemoradiotherapy and ASCT may overcome the prognostic importance of biologic markers in relapsed/refractory Hodgkin's lymphoma. *Appl Immunohistochem Mol Morphol* 2010 Jan;18(1):35-40. PMID: 19701081.
6. Schaffel R, Hedvat CV, Teruya-Feldstein J, **Persky D**, Maragulia J, Lin D, Portlock CS, Moskowitz CH, Zelenetz AD. Prognostic impact of proliferative index determined by quantitative image analysis and the mantle cell lymphoma International Prognostic Index in patients with mantle cell lymphoma. *Ann Oncol*, 2010 Jan;21(1):133-9. PMID: 20019090; PMCID: PMC2795614.
7. Stasik C, Nitta H, Zhang W, Mosher C, Cook J, Tubbs R, Unger J, Brooks T, **Persky DO**, Wilkinson S, Grogan T, Rimsza L. Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma. *Haematologica*, 2010 April; 95(4): 597-603. PMID: 20378577; PMCID: PMC2857189.
8. Koreishi AF, Saenz AJ, **Persky DO**, Cui H, Moskowitz A, Moskowitz CH, Teruya-Feldstein J. The role of cytotoxic and regulatory t cells in relapsed/refractory Hodgkin lymphoma. *Appl Immunohistochem Mol Morphol*, 2010 May;18(3):206-11. PMID: 20065852; PMCID: PMC3260943.
9. Qi W, Cooke LS, Liu X, Rimsza L, Roe DJ, **Persky DO**, Miller TP, Mahadevan D. Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma. *Biochem Pharmacol*. 2011 Apr 1;81(7):881-90. Epub 2011 Feb 1. PMID: 21291867; PMCID: PMC3792566.
10. Qi W, Liu X, Cooke LS, **Persky DO**, Miller TP, Squires M, Mahadevan D. AT9283, a novel aurora kinase inhibitor suppresses tumor growth in aggressive B-cell lymphomas. *Int J Cancer* 2011 Jul 27. doi: 10.1002/ijc.26324 [Epub ahead of print] PMID: 21796626.
11. **Persky DO**, Dornan D, Goldman BH, Brazier RM, Fisher RI, LeBlanc M, Maloney DG, Press OW, Miller TP, Rimsza LM. Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. *Haematologica* 2012 Jun;97(6):937-42. Epub 2012 Jan 22. PMID 22271896; PMCID 3366663.

Comment in: "Fc gamma receptor 3a genotype in follicular lymphoma: the end of the story?" Reply to "Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone". *Haematologica*. 2012;97(6):937-942. PMID 23125245; PMCID: PMC3487428.

12. Mahadevan D, Unger JM, Spier CM, **Persky DO**, Young F, Leblanc M, Fisher RI, Miller TP. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. *Cancer*. 2013 Jan 15;119(2):371-9. Epub 2012 Jul 25. PMID 22833464; PMCID: PMC3485430.
13. Qi W, Spier C, Liu X, Agarwal A, Cooke LS, **Persky DO**, Chen D, Miller TP, Mahadevan D. Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment. *Leuk Res*. 2013 Apr;37(4):434-9. Epub 2012 Nov 12. PMID 23153524; PMCID: PMC3816641.
14. Cycon KA, Mulvaney K, Rimsza LM, **Persky D**, Murphy SP. Histone deacetylase inhibitors activate CIITA and major histocompatibility complex class II antigen expression in diffuse large B cell lymphoma. *Immunology*. 2013 Jun 21. PMID: 23789844; PMCID: PMC3784172.
15. Friedberg JW, Mahadevan D, Jung J, Cebula E, **Persky D**, Lossos I, Agarwal AG, Zhou X, Leonard EJ, Bernstein SH. Phase 2 study of alisertib, a selective aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphoma. *J Clin Oncol*. 2014 Jan 1;32(1):44-50. PMID: 24043741; PMCID: PMC3867644.

D. Research Support

Ongoing Research Support:

SAHA (NSC-701852) Persky (PI) 10/10 – (Ongoing)
Southwest Oncology Group 0806
A phase I/II trial of Vorinostat in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma
Role: PI

Southwest Oncology Group 1001 Persky (PI) 09/11 – (Ongoing)
A Phase II Trial of PET-directed Therapy for Early Stage Diffuse Large B-Cell Lymphoma
Role: PI

Southwest Oncology Group/Merck Persky (PI) 10/10 – (Ongoing)
SWOG 0806. A phase I/II trial of Vorinostat (SAHA) (NSC-701852) In Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (translational medicine)
Role: Co-PI

Completed Research Support:

Hope Foundation Persky (PI) 10/10 – 10/12
Coltman Award (Career Development)
The goal of this award is to conduct research to increase survival rates for patients with diffuse large B-cell lymphoma (DLBCL), the most common non-Hodgkin's lymphoma.
Role: PI

GlaxoSmithKline 05/12 – 07/12
A Phase II, Multi-Centre Study Investigating the Safety and Efficacy of Ofatumumab and Bendamustine Combination in Patients with Untreated or Relapsed Chronic Lymphocytic Leukemia (CLL)
Role: Site PI

C14011 Millennium Pharmaceuticals 07/11 – 06/12
A Multicenter Phase I/II Study of MLN8237, an Oral Aurora A Kinase Inhibitor, in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma Treated with Rituximab and Vincristine.
Role: Site PI

Millennium Pharmaceuticals 06/09 – 06/12
A Phase II Trial of MLN8237, an Oral Aurora A Kinase Inhibitor, in Adult Patients with Aggressive Non-Hodgkin's Lymphoma
Role: Site PI

P50 CA130805-01A1 Fisher (PI) 07/08 – 06/12
SPORE in lymphoma. Targeting Aurora Kinase in Aggressive B-cell non-Hodgkin's Lymphomas
The goal of this project was to determine whether targeting Aurora with a specific small molecular inhibitor might be of therapeutic value in aggressive B-cell non-Hodgkin's lymphomas.
Role: Clinical Investigator, Project 1

X05260 Persky (PI) 05/09 – 06/12
Investigator-Initiated. A Phase II, Open-Label Study of Bortezomib (Velcade), Cladribine and Rituximab (VCR) in advanced, newly diagnosed and relapsed/refractory Mantle Cell and Indolent lymphomas
Role: PI

P01 CA017094-32 Dorr (PI) 09/11- 06/12
Therapeutic Targeting of Hypoxic and Oxidative Stress
The goal of this project is to develop entirely new classes of cyanoaziridine-based anticancer agents with redox mechanisms of action that induce apoptosis via novel pathways. Analogs are evaluated for antitumor activity and for molecular mechanisms of action.
Role: Clinical Leader, Core D

P01 CA130805 Fisher (PI) 04/09 – 04/11
SPORE in Lymphoma Developmental Research Award. Targeting Hypoxia in Lymphoma – Investigation of TH-302
The goal of this project was to investigate the in vitro activity of the hypoxia activated pro-drug TH-302 in lymphoma cell line models. The activity of TH-302 was correlated with biomarkers of hypoxia and DNA damage response signaling.
Role: Co-Investigator

Abbott M10-166 03/09 – 03/11
A Phase I Study Evaluating the Safety of ABT-263 in combination with Rituximab in Subjects with CD20-positive Lymphoid Malignancies
Role: Site PI